ER stress pathways regulate T-cell allogeneic and anti-tumor responses
ER应激通路调节T细胞同种异体和抗肿瘤反应
基本信息
- 批准号:10430505
- 负责人:
- 金额:$ 21.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-01 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:ATF6 geneAddressAllogenicAntibodiesAntigen-Presenting CellsAntigensAntitumor ResponseB-LymphocytesBiologyCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCD8B1 geneCell SurvivalCellsDataDegenerative DisorderDendritic CellsDiseaseEndoplasmic ReticulumEnvironmentExhibitsFoundationsGenetic TranscriptionGoalsHealthHematologic NeoplasmsHomeostasisHumanImmune responseImmune systemImmunityIn VitroInflammatoryKnock-outKnowledgeMalignant NeoplasmsMalignant neoplasm of ovaryMediatingMetabolic DiseasesMitochondriaMusPathogenicityPathway interactionsPlayProteinsPublishingRegulationReportingRoleSignal TransductionSolidSolid NeoplasmSyngeneic Bone Marrow TransplantationT cell responseT-LymphocyteTestingantigen processingbasecancer cellcancer immunotherapychimeric antigen receptor T cellsconditional knockouteffector T cellendoplasmic reticulum stressexhaustionexperimental studygraft vs host diseasegraft vs leukemia effectimprovedin vivoleukemianovel strategiesprogramsprotein misfoldingresponsetumortumor microenvironment
项目摘要
Summary
Unfolded protein response (UPR) is a highly conserved pathway that allows the cell to manage endoplasmic
reticulum (ER) stress in response to protein misfolding. Three master regulators control the UPR: IRE1α,
PERK, and ATF6. The primary goal of UPR is to induce transcriptional and translational programs to maintain
ER homeostasis for cell survival. Thus, dysfunctional UPR signaling has been shown to contribute to various
health conditions including metabolic diseases, degenerative diseases, inflammatory disorders, and cancer.
The ER stress pathways have been studied in cancer cells extensively, but have been overall understudied in
T-cell immunity and tolerance. There are several knowledge gaps in understanding the impacts of the ER
stress pathways in T-cell immunity against cancer. Our long-term goal is to develop novel strategies through
targeting the ER stress pathways for improving cancer immunotherapy of human malignancies. the overall
objectives of this application are to provide critical information towards more understanding the impacts of ER
stress pathways on immune responses against cancer, which will eventually help to fulfill our long-term goal.
Our central hypothesis is that the IRE-1α/XBP-1 and PERK/CHOP pathways differentially regulate CD4 and
CD8 anti-tumor responses in microenvironment dependent manner. The hypothesis has been formulated
based on preliminary data generated from in vitro and in vivo experiments using genetically modified mice with
T-cell conditional knock-out (KO) for XBP-1, PERK or both. This hypothesis will be tested in the following two
Specific Aims: 1) To define the role of XBP-1 and PERK in T-cell mediated graft-versus-host (GVH) and graft-
versus-leukemia (GVL) responses; 2) To define the impact of XBP-1 and PERK in T-cell immunity against
tumor. The proposed study is expected to provide a strong guidance for improving T-cell based cancer
immunotherapy by targeting the ER stress pathways and to provide a solid foundation for further studying
underlying mechanisms of ER stress pathways in regulating T-cell immunity.
总结
未折叠蛋白反应(UPR)是一个高度保守的途径,允许细胞管理内质网
内质网(ER)应激反应蛋白质错误折叠。三个主调节器控制UPR:IRE 1 α,
还有ATF 6。UPR的主要目标是诱导转录和翻译程序,以维持
ER稳态对细胞存活的影响。因此,功能失调的UPR信号转导已被证明有助于各种
健康状况,包括代谢性疾病、退行性疾病、炎性疾病和癌症。
ER应激途径已在癌细胞中被广泛研究,但在癌症研究中总体上研究不足。
T细胞免疫力和耐受性。在理解ER的影响方面存在一些知识差距
T细胞抗肿瘤免疫中的应激途径。我们的长期目标是通过以下方式制定新策略
靶向ER应激途径以改善人类恶性肿瘤的癌症免疫疗法。整体
本应用程序的目标是提供关键信息,以更好地了解ER的影响
强调对抗癌症的免疫反应途径,这最终将有助于实现我们的长期目标。
我们的中心假设是IRE-1α/XBP-1和PERK/CHOP通路差异调节CD 4和CD 4 + T细胞,
以微环境依赖性方式的CD 8抗肿瘤应答。这个假设已经形成了
基于使用具有以下基因的转基因小鼠的体外和体内实验产生的初步数据,
XBP-1、PERK或两者的T细胞条件性敲除(KO)。这一假设将在以下两个实验中得到检验:
具体目的:1)确定XBP-1和PERK在T细胞介导的移植物抗宿主(GVH)和移植物抗宿主(GVH)中的作用。
2)为了确定XBP-1和PERK在T细胞免疫中对抗白血病(GVL)应答的影响,
肿瘤这项拟议的研究有望为改善基于T细胞的癌症提供强有力的指导
通过靶向ER应激通路的免疫治疗,并为进一步研究提供坚实的基础
ER应激途径在调节T细胞免疫中的潜在机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Xue-Zhong Yu其他文献
Xue-Zhong Yu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Xue-Zhong Yu', 18)}}的其他基金
Targeting PIM-2 Kinase for Improving Cancer Immunotherapy
靶向 PIM-2 激酶以改善癌症免疫治疗
- 批准号:
10364948 - 财政年份:2022
- 资助金额:
$ 21.88万 - 项目类别:
Targeting PIM-2 Kinase for Improving Cancer Immunotherapy
靶向 PIM-2 激酶以改善癌症免疫治疗
- 批准号:
10559633 - 财政年份:2022
- 资助金额:
$ 21.88万 - 项目类别:
Control of GVHD by Probiotics with individual Commensal Bacteria
益生菌与单个共生细菌控制 GVHD
- 批准号:
10434993 - 财政年份:2022
- 资助金额:
$ 21.88万 - 项目类别:
ER stress pathways regulate T-cell allogeneic and anti-tumor responses
ER应激通路调节T细胞同种异体和抗肿瘤反应
- 批准号:
10577856 - 财政年份:2022
- 资助金额:
$ 21.88万 - 项目类别:
Control of GVHD by Probiotics with individual Commensal Bacteria
益生菌与单个共生细菌控制 GVHD
- 批准号:
10617324 - 财政年份:2022
- 资助金额:
$ 21.88万 - 项目类别:
Targeting IRE-1a/XBP-1 Axis for Control of Chronic GVHD and Leukemia Relapse
靶向 IRE-1a/XBP-1 轴控制慢性 GVHD 和白血病复发
- 批准号:
10578550 - 财政年份:2018
- 资助金额:
$ 21.88万 - 项目类别:
Targeting IRE-1a/XBP-1 Axis for Control of Chronic GVHD and Leukemia Relapse
靶向 IRE-1a/XBP-1 轴控制慢性 GVHD 和白血病复发
- 批准号:
10179448 - 财政年份:2018
- 资助金额:
$ 21.88万 - 项目类别:
Separation of GVH and GVL Responses Using Alloreactive CD8 iTregs
使用同种异体反应性 CD8 iTreg 分离 GVH 和 GVL 反应
- 批准号:
9333524 - 财政年份:2017
- 资助金额:
$ 21.88万 - 项目类别:
Control of GVHD and Leukemia Relapse by Targeting Cell Metabolism
通过靶向细胞代谢控制 GVHD 和白血病复发
- 批准号:
8815578 - 财政年份:2015
- 资助金额:
$ 21.88万 - 项目类别:
MicroRNA Regulates Graft-versus-Host Disease
MicroRNA 调节移植物抗宿主病
- 批准号:
9206138 - 财政年份:2015
- 资助金额:
$ 21.88万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 21.88万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 21.88万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 21.88万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 21.88万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 21.88万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 21.88万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 21.88万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 21.88万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 21.88万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 21.88万 - 项目类别:
Research Grant